In the BioHarmony Drug Report Database

"Preview" Icon

Aripiprazole

Abilify (aripiprazole) is a small molecule pharmaceutical. Aripiprazole was first approved as Abilify on 2002-11-15. It is used to treat schizophrenia and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat bipolar disorder and schizophrenia. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 1D, histamine H1 receptor, 5-hydroxytryptamine receptor 1A, D(4) dopamine receptor, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 6, and albumin. Aripiprazole’s patents are valid until 2034-03-08 (FDA).

 

Trade Name

 

Abilify, Abilify Maintena
 

Common Name

 

aripiprazole
 

ChEMBL ID

 

CHEMBL1112
 

Indication

 

bipolar disorder, schizophrenia, schizophrenia spectrum and other psychotic disorders
 

Drug Class

 

Antiulcer agents (benzimidazole derivatives)

Image (chem structure or protein)

Aripiprazole structure rendering